Lck-IN-1

• UNSPSC Description:

  Lck-IN-1 is a potent lymphocyte protein tyrosine kinase (Lck) inhibitor extracted from patent WO2007013673A1, example 48[1].

• Target Antigen:

  Src

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/lck-in-1.html

• Purity:

  99.6

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCNC1=NN2C(C=C1)=NC=C2C3=CC=NC=C3

• Molecular Weight:

  253.30

• References & Citations:

  [1]Kazuo Nakai, et al. Fused heterocycles as lck inhibitors. WO2007013673A1.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  923596-52-5